MedTrace Logo

Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer

NCT04918186 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2026-05-12

No results posted yet for this study

Summary

This study is being done to answer the following question: What are the effects of a new drug or drugs on ovarian cancer? The pre-study screening may be done to test a sample of tissue for biomarkers to determine participation in the study.

Conditions

Interventions

DRUG

Durvalumab

1500mg IV, 60 min day 1 every 4 weeks

DRUG

BA3011

IV

DRUG

BA3021

IV

DRUG

ENB003

IV

DRUG

Toripalimab

IV

Sponsors & Collaborators

  • Cancer Research Institute, New York City

    collaborator OTHER

  • AstraZeneca

    collaborator INDUSTRY

  • BioAtla, Inc.

    collaborator INDUSTRY

  • Canadian Cancer Trials Group

    lead NETWORK

Principal Investigators

  • Helen MacKay · Sunnybrook Health Sciences Centre, Toronto, Ontario Canada

  • Anna Tinker · BCCA - Vancouver Cancer Centre, BC Canada

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-03
Primary Completion
2026-06-30
Completion
2026-12-31
FDA Drug
Yes

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04918186 on ClinicalTrials.gov